These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 30051230)
1. Is pharmacovigilance of biologicals cost-effective? Claus B Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230 [TBL] [Abstract][Full Text] [Related]
2. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies. Francescon S; Fornasier G; Baldo P Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558 [TBL] [Abstract][Full Text] [Related]
3. Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice. Vermeer NS; Giezen TJ; Zastavnik S; Wolff-Holz E; Hidalgo-Simon A Clin Pharmacol Ther; 2019 Apr; 105(4):962-969. PubMed ID: 30460997 [TBL] [Abstract][Full Text] [Related]
4. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832 [TBL] [Abstract][Full Text] [Related]
5. Current state of biologic pharmacovigilance in the European Union: improvements are needed. Felix T; Jordan JB; Akers C; Patel B; Drago D Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424 [TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance in China: development and challenges. Zhao Y; Wang T; Li G; Sun S Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225 [TBL] [Abstract][Full Text] [Related]
7. Pharmacovigilance in Europe. Johnson CL; Hutchinson JA Transplantation; 2015 Aug; 99(8):1542-3. PubMed ID: 26308299 [No Abstract] [Full Text] [Related]
8. EU's new pharmacovigilance legislation: considerations for biosimilars. Calvo B; Zuñiga L Drug Saf; 2014 Jan; 37(1):9-18. PubMed ID: 24190573 [TBL] [Abstract][Full Text] [Related]
9. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review. Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291 [TBL] [Abstract][Full Text] [Related]
10. Biosimilars: A consideration of the regulations in the United States and European union. Daller J Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800 [TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance in developing countries (part I): importance and challenges. Elshafie S; Zaghloul I; Roberti AM Int J Clin Pharm; 2018 Aug; 40(4):758-763. PubMed ID: 29248988 [TBL] [Abstract][Full Text] [Related]
12. Biosimilars: A new scenario in biologic therapies. Serra López-Matencio JM; Morell Baladrón A; Castañeda S Reumatol Clin; 2017; 13(5):287-293. PubMed ID: 27372258 [TBL] [Abstract][Full Text] [Related]
13. [Biologicals and Biosimilars: Gaps in the Pharmacovigilance System in Portugal]. Portela MC; Sinogas C; Almeida FA; Baptista-Leite R; Castro-Caldas A Acta Med Port; 2017 Mar; 30(3):205-212. PubMed ID: 28550830 [TBL] [Abstract][Full Text] [Related]
14. Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions. Correia Pinheiro L; Giezen TJ; Wolff-Holz E; Weise M; Laslop A; Hidalgo-Simon A Clin Pharmacol Ther; 2021 Nov; 110(5):1311-1317. PubMed ID: 34472087 [TBL] [Abstract][Full Text] [Related]
15. Pharmacovigilance in developing countries (part II): a path forward. Elshafie S; Roberti AM; Zaghloul I Int J Clin Pharm; 2018 Aug; 40(4):764-768. PubMed ID: 29322474 [TBL] [Abstract][Full Text] [Related]
16. Biologicals and biosimilars: safety issues in Europe. Portela MDCC; Sinogas C; Albuquerque de Almeida F; Baptista-Leite R; Castro-Caldas A Expert Opin Biol Ther; 2017 Jul; 17(7):871-877. PubMed ID: 28540760 [TBL] [Abstract][Full Text] [Related]
17. Biosimilars: pharmacovigilance and risk management. Zuñiga L; Calvo B Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204 [TBL] [Abstract][Full Text] [Related]
18. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions. Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924 [TBL] [Abstract][Full Text] [Related]
19. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes. Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963 [TBL] [Abstract][Full Text] [Related]
20. A review of the United States' naming convention for biological products. Saunders J; Proctor C; Shermock KM Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):750-753. PubMed ID: 32319139 [No Abstract] [Full Text] [Related] [Next] [New Search]